Skip to content


Inke Tirkkonen.png

Inke Tirkkonen: The Phase1 trainee programme has allowed me to experience how work in drug safety requires great precision and that it is also highly relevant and meaningful

9/29/2023 We are Orion

Internal mobility has enabled Ville, Master of Science in mechanical engineering, to have a varied career at Orion

9/29/2023 We are Orion
Maija Väätäjä.png

Maija Väätäjä: The people and truly meaningful work have been the best aspects of Orion’s Phase1 trainee programme

9/21/2023 We are Orion

What is a generic medicine – and what is good to know about it?

9/21/2023 Your Health
Illustration image.png

Change in Orion Group's Half-Year Financial Report 2024 publication date 

9/20/2023 Stock exchange release
Damla Serper.png

Damla Serper: As a Phase1 trainee, I have been happy to work on a project where I can integrate my research into industrial set-up

9/15/2023 We are Orion

Even a short job rotation period can be invigorating and develop professional skills

9/14/2023 We are Orion

A biosimilar has the same efficacy and safety as a biological proprietary drug

9/12/2023 Your Health

Finland’s good reputation attracted Bryce Nelson to work in Finland

9/7/2023 We are Orion

Can Hekim studies mechanisms that help the human immune system defend itself against cancer

9/5/2023 We are Orion
Illustration image.png

24 000 Orion Corporation A shares converted into B shares

9/4/2023 Stock exchange release

The popular Phase1 trainee programme offers university students a sense of community and professionally challenging tasks

9/1/2023 We are Orion
Illustration image.png

Orion Corporation: Managers’ transactions – Hilpi Rautelin

8/30/2023 Managers transactions
Illustration image.png

Change in Orion Group Executive Management Board as of February 1st, 2024 – Julia Macharey appointed Senior Vice President, People & Culture

8/22/2023 Stock exchange release

Orion has started building a virtual pharmaceutical research ecosystem in Finland

8/22/2023 Science and Partnering

Versatile and talented Tapani returned to Orion after many years equipped with lessons learnt from the banking world

8/18/2023 We are Orion
Illustration image.png

European Commission approval of Ztalmy® (ganaxolone) for the adjunctive treatment of epileptic seizures associated with CDKL5 deficiency disorder

7/31/2023 Press release
Illustration image.png

Orion Corporation: Managers’ transactions – Kari Jussi Aho

7/27/2023 Managers transactions